文献速递甲状腺疾病

依维莫司治疗晚期滤泡源性甲状腺癌患者:一项II期临床试验结果

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

这项前瞻性II期试验纳入28例进展性转移性或局部晚期放射性难治性分化型甲状腺癌患者和7例未分化甲状腺癌患者,口服依维莫司10 mg每日一次。中位随访38个月,17例(65%)达疾病稳定,其中15例(58%)疾病稳定超过24周,无完全或部分缓解;中位无进展生存期9个月,中位总生存期18个月;毒性以1/2级为主。

要点

  • 28例分化型甲状腺癌和7例未分化甲状腺癌患者接受依维莫司10 mg每日一次口服。
  • 17例(65%)达疾病稳定,其中15例(58%)疾病稳定超过24周,无完全或部分缓解。
  • 中位无进展生存期9个月,中位总生存期18个月;骨转移对生存有负面影响。

核心结论

  • 依维莫司在晚期分化型甲状腺癌患者中具有临床相关的抗肿瘤活性。
  • 鉴于观察到的疾病控制率和相对较低的毒性,有必要在这些患者中进一步研究依维莫司序贯或联合治疗。

研究设计与样本

  • 前瞻性II期临床试验,纳入28例进展性转移性或局部晚期放射性难治性分化型甲状腺癌患者和7例未分化甲状腺癌患者。
  • 患者接受依维莫司10 mg口服每日一次。
  • 主要终点为疾病控制率(完全缓解+部分缓解+疾病稳定超过24周)。
  • 次要终点包括无进展生存期、总生存期、毒性以及突变和药代动力学相关结局。

主要发现

  • 中位随访时间38个月(范围2-64个月)。
  • 17例(65%)达疾病稳定,其中15例(58%)疾病稳定超过24周;未观察到完全缓解或部分缓解。
  • 中位无进展生存期9个月(95%CI:4至14),中位总生存期18个月(95%CI:7至29)。
  • 骨转移的存在对生存有负面影响。
  • 毒性主要为1/2级,包括贫血(64%)、咳嗽(64%)、口腔炎(61%)和高血糖(61%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mammalian target of rapamycin (mTOR) upregulation has been reported to be involved in the pathogenesis of thyroid tumors, and treatment with the mTOR inhibitor everolimus has shown promising results in endocrine tumors. We conducted a prospective phase II clinical trial to determine the efficacy and safety of everolimus in patients with advanced follicular-derived thyroid cancer. PATIENTS AND METHODS: Twenty-eight patients with progressive metastatic or locally advanced radioactive refractory differentiated thyroid cancer and 7 patients with anaplastic thyroid cancer were included and received everolimus 10 mg orally once daily. The primary endpoint was disease control rate [complete (CR) + partial response (PR) + stable disease (SD) > 24 weeks]. Secondary endpoints included progression-free survival (PFS), overall survival (OS), toxicity, and mutational and pharmacokinetic-related outcomes. RESULTS: Median follow-up duration was 38 months (2-64). Seventeen patients (65%) showed SD, of which 15 (58%) showed SD >24 weeks. No CR or PR was observed. Median PFS and OS were 9 [95% confidence interval (CI): 4 to 14] and 18 (95% CI: 7 to 29) months, respectively. Survival was negatively influenced by the presence of bone metastases. Toxicity was predominantly grade 1/2 and included anemia (64%), cough (64%), stomatitis (61%), and hyperglycemia (61%). Duration of SD was related to everolimus exposure. The presence of somatic gene variants related to mTOR signaling did not clearly stratify for responses. CONCLUSION: Everolimus has clinically relevant antitumor activity in patients with advanced differentiated thyroid cancer. Given the observed disease control rate and the relatively low toxicity profile, further investigation of everolimus in sequential or combination therapy in these patients is warranted.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Schneider TC, de Wit D, Links TP, et al. Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. J Clin Endocrinol Metab. 2017. PMID: 27870581. doi:10.1210/jc.2016-2525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。